Isosorbide Mononitrate - Uses, Dose, MOA, Brands, Side effects

Isosorbide mononitrate causes vasodilation of blood vessels. It has direct vasodilatory effects on coronary blood vessels and is used in patients with angina or chest pain.

Isosorbide mononitrate Uses:

  • Angina pectoris:

    • Used for treatment (immediate-release only) & prevention of coronary artery disease-induced angina pectoris.

Note: Cannot be used to abort an acute anginal attack as its onset of action is not sufficiently rapid. Off Label Use of Isosorbide mononitrate in Adults:

    • HFrEF (Heart failure with reduced ejection fraction)

Isosorbide mononitrate dose in Adults:

Isosorbide mononitrate dose in the treatment of Angina pectoris: Oral:

Note: Chronic exposure results in tolerance to nitrates and this effect is not overcome by dose escalation. The only way to overcome tolerance is by short periods of nitrate absence from the body. Nitrate-free intervals of 14 or more hours (immediate-release products) or more than 18 hours (sustained-release products) may help minimize tolerance.

  • Immediate release:

    • 20 mg twice a day with the 2 doses given 7 hours apart (eg, 9 AM and 4 PM) to decrease tolerance development of tolerance; small-statured patients may begin therapy with 5 mg twice a day and titrate to at least 10 mg twice a day in first 2 to 3 days of therapy.
  • Extended-release:

    • Initial: 30 to 60 mg once a day in the morning; after several days, may titrate to 120 mg once a day; rarely, dose as high as 240 mg once a day may be required.

Isosorbide mononitrate dose in the treatment of Heart failure with reduced ejection fraction (off-label):

Note:

  • As an additional therapy for persistent NYHA class III or IV heart failure with reduced ejection fraction (HFrEF) when symptoms are not controlled despite optimal medical therapies or in patients with tolerance issues to an ACE inhibitor, angiotensin II receptor blocker (ARB), or angiotensin II-neprilysin inhibitor (ARNI).
  • Although ACCF/AHA guidelines have recommended isosorbide dinitrate in combination with hydralazine, some experts, for the sake of reduction of pill burden and improvement of adherence, have substituted isosorbide mononitrate for isosorbide dinitrate.

Oral:

  • Extended-release:

    • Initial: 30 to 60 mg once a day with hydralazine 3 or 4 times a day; dose should be titrated every 2 to 4 weeks with a maximum dose: 120 mg once a day.
    • Note: Use of the fixed-dose combination of isosorbide dinitrate/hydralazine instead of separate components may also be considered.

Dose in Children:

Not indicated.


Pregnancy Risk Factor B

  • Certain adverse events have been observed in animal reproduction studies.
  • The use of nitric oxide donors, such as isosorbide for cervical ripening and pre-eclampsia has been evaluated.

Use during breastfeeding:

  • It is not known if there is isosorbide mononitrate in breast milk.
  • Manufacturer suggests being cautious when giving isosorbide mononitrates to nursing mothers.

Dose in Kidney Disease:

Dosage adjustment is not necessary.

  • Hemodialysis: No Supplemental dose is not required. Dose after dialysis.
  • Continuous ambulatory peritoneal dialysis: Supplemental dose is not required.

Dose in Liver disease:

Dosage adjustment is not necessary.


Common Side Effects of Isosorbide mononitrate:

  • Central nervous system:

    • Headache
    • Dizziness

Less Common Side Effects of Isosorbide mononitrate:

  • Cardiovascular:

    • Abnormal Heart Sounds
    • Atrial Arrhythmia
    • Atrial Fibrillation
    • Bradycardia
    • Bundle Branch Block
    • Cardiac Arrhythmia
    • Cardiac Failure
    • Chest Pain
    • ECG Abnormality
    • Edema
    • Exacerbation Of Angina Pectoris
    • Extrasystoles
    • Flushing
    • Heart Murmur
    • Hypertension
    • Hypotension
    • Intermittent Claudication
    • Myocardial Infarction
    • Palpitations
    • Tachycardia
    • Varicose Veins
    • Ventricular Tachycardia
    • Cardiovascular Toxicity
  • Central Nervous System:

    • Anxiety
    • Confusion
    • Depression
    • Drowsiness
    • Fatigue
    • Hypoesthesia
    • Insomnia
    • Lack Of Concentration
    • Malaise
    • Migraine
    • Myasthenia
    • Nervousness
    • Neuritis
    • Nightmares
    • Paresis
    • Paresthesia
    • Rigors
    • Vertigo
    • Pain
    • Emotional Lability
  • Dermatologic:

    • Abnormal Hair Texture
    • Acne Vulgaris
    • Diaphoresis
    • Leg Ulcer
    • Pruritus
    • Skin Rash
  • Endocrine & Metabolic:

    • Decreased Libido
    • Hot Flash
    • Hyperuricemia
    • Hypokalemia
  • Gastrointestinal:

    • Abdominal Pain
    • Constipation
    • Diarrhea
    • Dyspepsia
    • Flatulence
    • Gastric Ulcer
    • Gastric Ulcer With Hemorrhage
    • Gastritis
    • Glossitis
    • Hemorrhoids
    • Loose Stools
    • Melena
    • Nausea
    • Vomiting
    • Xerostomia
  • Genitourinary:

    • Atrophic Vaginitis
    • Impotence
    • Mastalgia
    • Urinary Tract Infection
  • Hematologic & Oncologic:

    • Hypochromic Anemia
    • Nonthrombocytopenic Purpura
    • Thrombocytopenia
  • Hepatic:

    • Increased Serum Alanine Aminotransferase
    • Increased Serum Aspartate Aminotransferase
  • Hypersensitivity:

    • Hypersensitivity Reaction
  • Infection:

    • Bacterial Infection
    • Candidiasis
    • Viral Infection
  • Neuromuscular & Skeletal:

    • Arthralgia
    • Asthenia
    • Back Pain
    • Musculoskeletal Pain
    • Myalgia
    • Myositis
    • Shoulder Stiffness
    • Tendon Disease
    • Torticollis
    • Tremor
  • Ophthalmic:

    • Blepharoptosis
    • Conjunctivitis
    • Photophobia
    • Visual Disturbance
  • Otic:

    • Otalgia
    • Perforated Tympanic Membrane
    • Tinnitus
  • Renal:

    • Nephrolithiasis
    • Polyuria
  • Respiratory:

    • Bronchitis
    • Bronchospasm
    • Cough
    • Dyspnea
    • Flu-Like Symptoms
    • Increased Bronchial Secretions
    • Nasal Congestion
    • Pharyngitis
    • Pneumonia
    • Pulmonary Infiltrates
    • Rales
    • Rhinitis
    • Sinusitis
    • Upper Respiratory Infection
    • Increased Cough
  • Miscellaneous:

    • Fever
    • Nodule

Contraindications to Isosorbide mononitrate:

  • Hypersensitivity (To isosorbide mononitrate and any other component of the formulation).
  • Use concurrently with phosphodiesterase inhibitors such as tadalafil (sildenafil), vardenafil or avanafil).
  • Concurrent use of riociguat

Canadian labeling: Additional contraindications not in US labeling

  • Shock and collapsing states (acute circulation failure associated with severe hypotension).
  • Orthostatic hypotension
  • Any obstruction that causes myocardial dysfunction (eg, constrictive or mitral stenosis, aortic or mitral blockage)
  • Elevated intracranial pressure
  • Severe anemia.

Warnings and precautions

  • CNS depression:

    • It is possible to develop CNS depression from its use, which can cause impairment of physical or mental capabilities.
    • Patients should be aware of tasks that require mental alertness, such as driving or operating machinery.
  • Hypotension/bradycardia:

    • This can lead to severe hypotension, paradoxical bradycardia, and worsening angina pectoris.
    • It can also lead to orthostatic hypotension, which can be made worse by ethanol.
    • Be cautious in hypotension and volume depletion. Extreme caution is advised for inferior wall MI and right ventricular infarctions.
    • Even small amounts can lead to severe hypotension, especially if you are upright.
  • The intracranial pressure rose:

    • An increase in intracranial pressure could be caused or exacerbated by the use nitrates.
    • This may then be linked to worse outcomes for patients with neurologic injuries (eg, intracranial bleeding, traumatic brain injury).
  • Cardiovascular disease

    • There are no studies available so it is not recommended for patients with acute myocardial injury (MI) or heart disease (has not been researched).
    • Use caution when there is volume depletion or moderate hypotension
    • You should exercise extreme caution when dealing with inferior wall MI or suspected right ventricular Infarctions.
    • Canadian labeling prohibits the use of this medication in acute circulatory failure, marked hypotension, postural hypertension, and myocardial dysfunction due to obstruction (eg in the presence aortic, mitral, or constrictive pericarditis).
  • Hypertrophic cardiomyopathy, (HCM)

    • Patients with HCM and outflow tract obstruction should avoid nitrates.
    • They can reduce preload, exacerbate obstruction, hypotension, syncope, and/or worsening heart failure.

Isosorbide mononitrate: Drug Interaction

Risk Factor C (Monitor therapy)

Alcohol (Ethyl)

May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).

Aprepitant

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Bosentan

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

Clofazimine

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

CYP3A4 Inducers (Moderate)

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

CYP3A4 Inhibitors (Moderate)

May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).

Dapoxetine

May enhance the orthostatic hypotensive effect of Vasodilators (Organic Nitrates).

Dapsone (Topical)

May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents.

Deferasirox

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

Duvelisib

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Erdafitinib

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

Erdafitinib

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Fosaprepitant

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Fosnetupitant

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Ivosidenib

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

Larotrectinib

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Local Anesthetics

Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased.

Molsidomine

May enhance the hypotensive effect of Vasodilators (Organic Nitrates).

Netupitant

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Nitric Oxide

May enhance the adverse/toxic effect of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia.

Palbociclib

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Prilocaine

Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor patients for signs of methemoglobinemia (e.g., hypoxia, cyanosis) when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid lidocaine/prilocaine in infants receiving such agents.

Rilmenidine

Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Rilmenidine.

Rosiglitazone

Vasodilators (Organic Nitrates) may enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of ischemia and other adverse effects has been associated with this combination in some pooled analyses.

Sarilumab

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

Siltuximab

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

Simeprevir

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Sodium Nitrite

Methemoglobinemia Associated Agents may enhance the adverse/toxic effect of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia.

Tocilizumab

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers).

Risk Factor D (Consider therapy modification)

CYP3A4 Inducers (Strong)

May increase the metabolism of CYP3A4 Substrates (High risk with Inducers). Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.

CYP3A4 Inhibitors (Strong)

May decrease the metabolism of CYP3A4 Substrates (High risk with Inhibitors).

Dabrafenib

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Seek alternatives to the CYP3A4 substrate when possible. If concomitant therapy cannot be avoided, monitor clinical effects of the substrate closely (particularly therapeutic effects).

Enzalutamide

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Concurrent use of enzalutamide with CYP3A4 substrates that have a narrow therapeutic index should be avoided. Use of enzalutamide and any other CYP3A4 substrate should be performed with caution and close monitoring.

Lorlatinib

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Avoid concurrent use of lorlatinib with any CYP3A4 substrates for which a minimal decrease in serum concentrations of the CYP3A4 substrate could lead to therapeutic failure and serious clinical consequences.

MiFEPRIStone

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Minimize doses of CYP3A4 substrates, and monitor for increased concentrations/toxicity, during and 2 weeks following treatment with mifepristone. Avoid cyclosporine, dihydroergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, and tacrolimus.

Mitotane

May decrease the serum concentration of CYP3A4 Substrates (High risk with Inducers). Management: Doses of CYP3A4 substrates may need to be adjusted substantially when used in patients being treated with mitotane.

Stiripentol

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors). Management: Use of stiripentol with CYP3A4 substrates that are considered to have a narrow therapeutic index should be avoided due to the increased risk for adverse effects and toxicity. Any CYP3A4 substrate used with stiripentol requires closer monitoring.

Risk Factor X (Avoid combination)

Conivaptan

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Fusidic Acid (Systemic)

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Idelalisib

May increase the serum concentration of CYP3A4 Substrates (High risk with Inhibitors).

Phosphodiesterase 5 Inhibitors

May enhance the vasodilatory effect of Vasodilators (Organic Nitrates).

Riociguat

Vasodilators (Organic Nitrates) may enhance the hypotensive effect of Riociguat.

 

Monitor:

  • Bp
  • Pulse rate

How to administer Isosorbide mononitrate?

  • Should not be administered around the clock.
  • Schedule immediate-release tablet twice a day with doses 7 hours apart (9 AM and 4 PM); extended-release tablet should be administered once a day with a half-glassful of fluid in the morning upon rising.
  • Do not chew or crush extended-release tablets should not be chewed or crushed; may be divided in half.
  • The extended-release tablets that are scored may be split due to insoluble matrix embedding.

Mechanism of action of Isosorbide mononitrate:

  • Nitroglycerin, and other nitrates can create free radical nitric oxygen. 
  • Nitric oxide activates smooth muscle's guanylate cyclease, which causes an increase in guanosine 5' monophosphate (cGMP).
  • This leads to the dephosphorylation and relaxation of myosin light chain light chains.
  • It causes vasodilation of both the veins and arteries, with predominant effects on veins. 
  • It causes a decrease in cardiac oxygen demand (left ventricular preload) and may also cause a slight reduction in afterload.

The onset of action:

  • 30 - 45 mins

Duration:

  • Immediate release: ≥6 hours
  • Extended-release: ≥12 - 24 hours

Absorption: Absorption is rapid and complete Distribution:

  • V : nearly 0.6 L/kg

Protein binding:

  • Less than 5% drug is protein-bound

Metabolism:

  • Mostly in liver

Bioavailability:

  • Almost 100%

Half-life elimination:

  • 5 - 6 hours

Time to peak

  •  plasma: 30 - 60 mins

Excretion:

  • Predominantly excreted inurine (2% as unchanged drug)
  • feces (1%)

International Brand Names of Isosorbide mononitrate:

  • APO-ISMN
  • Imdur
  • ISMN
  • PMS-ISMN
  • PRO-ISMN-60
  • AngiFix
  • Angifree SR
  • Angirest
  • Angisor
  • Angistad
  • Angitrate
  • ApoISMN
  • Cardismo
  • Cardisorb
  • Cardoxx
  • Cincordil
  • Conpin
  • Corangin
  • Corangin SR
  • Coronur
  • Coronur Retard
  • Coxine
  • Coxine SR
  • Danlixin
  • Duride
  • Effox
  • Elan
  • Elantan
  • Elantan LA
  • Elantan Long
  • Elonton SR
  • Imdex
  • Imdex CR
  • Imdur
  • Imdur 60
  • Imdur Durules
  • Imtrate
  • Ismexin
  • ISMN
  • ISMN AL
  • ISMN Genericon
  • ISMN Pharmavit
  • Ismo
  • ISMO
  • Ismo 20
  • Ismo-20
  • Ismodin
  • Ismox
  • Isobid
  • Isocard
  • Isolan
  • Isomel
  • Isomon
  • Isomonat
  • Isomonit
  • Isomonit Retard
  • Isonate
  • Isopen-20
  • Isorat
  • Isosorbide
  • Isospan SR
  • Isotril ER
  • MNI
  • Monicor
  • Monis
  • Monis-XR
  • Monit
  • Monit 20
  • Mono Corax
  • Mono Corax Retard
  • Mono Mack
  • Mono-Mack
  • Mono-Sanorania
  • Monobide
  • Monocinque
  • Monocinque Retard
  • Monoclair
  • Monocord 40
  • Monocord 50 SR
  • Monodur Durules
  • Monoket
  • Monoket OD
  • Monoket Retard
  • Monolong
  • Mononit
  • Monopront
  • Monorem
  • Monosan
  • Monosorb
  • Monosorbitrate
  • Monosordil
  • Monotab
  • Monotrate
  • Monotrate OD
  • Montra
  • Nitramin
  • Olicard
  • Pentacard
  • Rangin
  • Solotrate
  • Solotrate SR
  • Sorbimon
  • Sorbinate SR
  • Sormon
  • Trangina XL
  • Unicard
  • Uniket
  • Vasotrate
  • Vasotrate-60 OD
  • Vasotrate-OD
  • Vasotrol
  • Xismox XL

Isosorbide mononitrate Brand Names in Pakistan:

Isosorbide mononitrate 10 mg in Pakistan

Isotrate Mass Pharma PVT LTD

 

Isosorbide mononitrate 20 mg in Pakistan

CORLET BRYON PHARMACEUTICALS (PVT) LTD.
ELANTAN ATCO LABORATORIES LIMITED
FLO WILSONS PHARMACEUTICALS
ISMO 20 ROCHE PAKISTAN LTD.
ISODIL ROTEX MEDICA PAKISTAN (PVT) LTD
ISOMON PHARMATEC PAKISTAN (PVT) LTD.
ISOTAB EFROZE CHEMICAL INDUSTRIES (PVT) LTD.
ISOTIME-20 SCOTMANN PHARMACEUTICALS
ISOTRATE MASS PHARMA (PRIVATE) LIMITED
MONIS MAPLE PHARMACEUTICALS (PVT) LTD
MONIS MAPLE PHARMACEUTICALS (PVT) LTD
MONO CARD VALOR PHARMACEUTICALS
MONOSORBID BROOKES PHARMACEUTICAL LABORATORIES (PAK.) LTD.
SEQUENCE WERRICK PHARMACEUTICALS
SORBIMON ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.
SORBIMON ZAFA PHARMACEUTICAL LABORATORIES (PVT) LTD.
UNITRATE BENSON PHARAMCEUTICALS.
VASOCORD STERN PHARMA
VASOCORD STERN PHARMA

 

Isosorbide mononitrate 40 mg in Pakistan

CORLET BRYON PHARMACEUTICALS (PVT) LTD.
ELANTAN ATCO LABORATORIES LIMITED
ISOTAB EFROZE CHEMICAL INDUSTRIES (PVT) LTD.
ISOTRATE MASS PHARMA (PRIVATE) LIMITED
ISOTRATE MASS PHARMA (PRIVATE) LIMITED
MONIS MAPLE PHARMACEUTICALS (PVT) LTD
MONIS MAPLE PHARMACEUTICALS (PVT) LTD
MONOTAB EPLA LABORATORIES (PVT) LTD.
VASOCORD STERN PHARMA

 

Isosorbide mononitrate 60 mg in Pakistan

IMDUR BARRETT HODGSON PAKISTAN (PVT) LTD.
ISOTAB-XR EFROZE CHEMICAL INDUSTRIES (PVT) LTD.
MONIS-XR MAPLE PHARMACEUTICALS (PVT) LTD
MONOSOR XL UNIMARK PHARMACEUTICALS
SEQUENCE WERRICK PHARMACEUTICALS

 

Isosorbide mononitrate SR Tablets 60 mg in Pakistan

MONOSORBID BROOKES PHARMACEUTICAL LABORATORIES (PAK.) LTD.
VASOCORD STERN PHARMA

 

Isosorbide mononitrate 50 mg Capsules in Pakistan

ELANTAN LONG ATCO LABORATORIES LIMITED

 

Isosorbide mononitrate 20 mg and 40 mg Capsules in Pakistan

Savdil Pharmevo PVT LTD

 

Isosorbide mononitrate 60 mg Capsules in Pakistan

Isotime-60 Scotman Pharma
Savdil Pharmevo PVT LTD

Comments

NO Comments Found